Join Us

We are 224,438 members in 83 forums discussing 163,551 topics.

Help with Abbreviations

Topic: ESMO 2021 Coverage

Forum: Clinical Trials, Research News, Podcasts, and Study Results —

Share your research articles, interpretations and experiences here. Let us know how these studies affect you and your decisions.

Posted on: Sep 24, 2021 02:23PM

Moderators wrote:

Every year, the European Society for Medical Oncology Congress brings together clinicians, researchers, and advocates to discuss the latest cancer study results. We're proud to present our coverage below.

To send a Private Message to the Mods: community.breastcancer.org/mem...
Log in to post a reply

Page 1 of 1 (10 results)

Posts 1 - 10 (10 total)

Log in to post a reply

Sep 24, 2021 02:24PM Moderators wrote:

Adding Carboplatin to Chemotherapy Before Surgery Improves Early-Stage Triple-Negative Breast Cancer Outcomes
September 20, 2021

Adding carboplatin (brand name: Paraplatin) to the standard neoadjuvant chemotherapy regimen for early-stage triple-negative breast cancer improved event-free survival. Read more...

To send a Private Message to the Mods: community.breastcancer.org/mem...
Log in to post a reply

Sep 24, 2021 02:24PM Moderators wrote:

Enhertu Dramatically More Effective Than Kadcyla as Second Treatment for Metastatic HER2-Positive Breast Cancer
September 22, 2021

Enhertu more than doubled the 12-month progression-free survival rate than Kadcyla in people diagnosed with metastatic HER2-positive breast cancer that had been previously treated. Read more...

To send a Private Message to the Mods: community.breastcancer.org/mem...
Log in to post a reply

Oct 6, 2021 03:22PM Moderators wrote:

After 2-3 Years of Tamoxifen, 5 Years of Femara Offers More Benefits Than 2-3 Years
September 30, 2021

After taking tamoxifen for 2 to 3 years following surgery, postmenopausal women diagnosed with early-stage hormone-receptor-positive breast cancer had a better survival rate from taking 5 years of Femara rather than 2 to 3 years of Femara. Read more...

To send a Private Message to the Mods: community.breastcancer.org/mem...
Log in to post a reply

Oct 6, 2021 03:22PM Moderators wrote:

Adding Kisqali to Femara Improves Overall Survival for Postmenopausal Women With Advanced-Stage Hormone-Receptor-Positive HER2-Negative Breast Cancer
October 5, 2021

Adding Kisqali to Femara as a first treatment for advanced-stage hormone-receptor-positive HER2-negative breast cancer in postmenopausal women improved overall survival by more than 1 year. Read more...

To send a Private Message to the Mods: community.breastcancer.org/mem...
Log in to post a reply

Oct 6, 2021 03:22PM Moderators wrote:

Experimental Vic-Trastuzumab Duocarmazine Better Than Doctors' Treatment Choices for Pre-treated Advanced-Stage HER2-Positive Breast Cancer
October 5, 2021

The experimental targeted therapy medicine vic-trastuzumab duocarmazine improved progression-free survival and overall survival more than doctors' treatment choice for people diagnosed with advanced-stage HER2-positive breast cancer that had been previously treated with anti-HER2 medicine. Read more...

To send a Private Message to the Mods: community.breastcancer.org/mem...
Log in to post a reply

Oct 9, 2021 12:12PM Moderators wrote:

Adding Keytruda to Chemotherapy Improves Overall Survival in Metastatic, Strongly PD-L1-Positive Triple-Negative Breast Cancer
October 5, 2021

Adding the immunotherapy medicine Keytruda to chemotherapy improved overall survival more than chemotherapy alone in people diagnosed with metastatic triple-negative, strongly PD-L1-positive breast cancer, according to the KEYNOTE-355 study's final results. Read more...

To send a Private Message to the Mods: community.breastcancer.org/mem...
Log in to post a reply

Oct 9, 2021 12:12PM Moderators wrote:

Long-Term Side Effects Reduce Quality of Life Years After Cancer Diagnosis
October 5, 2021

About 4 years after being diagnosed with cancer, 14% of disease-free survivors were dissatisfied with the care they received for ongoing, long-term side effects of cancer treatment. Read more...

To send a Private Message to the Mods: community.breastcancer.org/mem...
Log in to post a reply

Oct 22, 2021 12:49PM Moderators wrote:

Breast Cancer Research at ESMO 2021

October 21, 2021

Brian wojciechowski md final 6340

Dr. Brian Wojciechowski practices medical oncology in Delaware County, Pennsylvania at Riddle, Taylor, and Crozer hospitals and also serves as Breastcancer.org's medical adviser. A native of South Philadelphia, he trained at Temple University School of Medicine and Lankenau Medical Center. Dr. Wojciechowski is a sought-after speaker on the topics of medical ethics and the biology of cancer.

Dr. Wojciechowski joined us to talk about some of the most notable research at the European Society for Medical Oncology Congress 2021.

Listen to the episode to hear Dr. Wojciechowski explain:

  • what an antibody-drug conjugate is
  • results from the DESTINY-Breast03 study, showing Enhertu more than doubled the 12-month progression-free survival rate compared to Kadcyla in people diagnosed with metastatic HER2-positive breast cancer that had been previously treated
  • results from the BrighTNess study, showing adding carboplatin to chemotherapy before surgery improves progression-free survival.

Running time: 14:09

Listen now or read the transcript.

To send a Private Message to the Mods: community.breastcancer.org/mem...
Log in to post a reply

Oct 22, 2021 12:53PM Moderators wrote:

Kisqali Plus Femara Seems Best Option for Advanced-Stage Hormone-Receptor-Positive HER2-Negative Breast Cancer

October 1, 2021

Hortobagyi gabriel

Dr. Gabriel Hortobagyi is professor of breast medical oncology at the University of Texas MD Anderson Cancer Center. He is a past president of the American Society of Clinical Oncology and is one of the world's leading authorities on breast cancer treatment. He has published more than 1,000 papers in peer-reviewed journals.

At the European Society for Medical Oncology Congress 2021, Dr. Hortobagyi presented overall survival results from the MONALEESA-2 trial, which compared the combination of Kisqali and Femara to Femara alone to treat advanced-stage hormone-receptor-positive HER2-negative breast cancer in postmenopausal women. Earlier results from the study found that adding Kisqali to Femara improved progression-free survival — the amount of time the women lived without the cancer growing. These new results found that the combination of Kisqali and Femara also improved overall survival — the length of time women lived whether the cancer grew or not.

Listen to the episode to hear Dr. Hortobagyi explain:

  • the goals of the MONALEESA-2 study
  • why the overall survival difference of more than 1 year is so important
  • whether the improvement in overall survival is likely to be the same no matter which aromatase inhibitor is used
  • what the results mean for postmenopausal women diagnosed with advanced-stage hormone-receptor-positive HER2-negative breast cancer

Running time: 19:47

Listen now or read the transcript.
To send a Private Message to the Mods: community.breastcancer.org/mem...
Log in to post a reply

Oct 22, 2021 12:54PM Moderators wrote:

Keytruda Added to Chemotherapy Improves Overall Survival for Metastatic PD-L1-Positive, Triple-Negative Breast Cancer

September 24, 2021

Rugo hope

Dr. Hope Rugo is professor of medicine in the division of hematology and oncology at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center, where she is also the director of breast oncology and clinical trials education. Dr. Rugo is also a member of the Breastcancer.org Professional Advisory Board. She is a principal investigator of a number of clinical trials looking at combining new targeted and immunotherapy medicines with standard treatments for both early-stage and advanced-stage breast cancer and has published hundreds of peer-reviewed papers.

At the European Society for Medical Oncology Congress 2021, Dr. Rugo presented final results from the KEYNOTE-355 trial, which was looking to see if Keytruda (chemical name: pembrolizumab) and chemotherapy were better than chemotherapy alone as a first treatment for metastatic PD-L1-positive, triple-negative breast cancer. Earlier results found that adding Keytruda to chemotherapy improved progression-free survival — how long people lived before the cancer grew — for this type of breast cancer. These new results show that adding Keytruda improves overall survival — how long people live whether the breast cancer grows or not.

Listen to the podcast to hear Dr. Rugo explain:

  • what the KEYNOTE-355 aimed to do
  • whether Keytruda offers benefits for PD-L1-negative disease
  • why it's important for a medicine to improve overall survival as well as progression-free survival
  • the differences in PD-L1 tests and what they mean for the effectiveness of breast cancer checkpoint inhibitor medicines

Running time: 25:03

Listen now or read the transcript.
To send a Private Message to the Mods: community.breastcancer.org/mem...

Page 1 of 1 (10 results)